Virtu Financial LLC Takes Position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

Virtu Financial LLC acquired a new position in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 172,665 shares of the biopharmaceutical company’s stock, valued at approximately $150,000.

A number of other institutional investors have also recently bought and sold shares of SGMO. Geode Capital Management LLC boosted its position in shares of Sangamo Therapeutics by 14.6% during the third quarter. Geode Capital Management LLC now owns 2,138,309 shares of the biopharmaceutical company’s stock worth $1,853,000 after purchasing an additional 272,123 shares in the last quarter. XTX Topco Ltd raised its stake in Sangamo Therapeutics by 167.8% during the 3rd quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company’s stock worth $90,000 after buying an additional 64,981 shares during the period. State Street Corp lifted its holdings in Sangamo Therapeutics by 28.0% during the third quarter. State Street Corp now owns 664,621 shares of the biopharmaceutical company’s stock worth $576,000 after acquiring an additional 145,400 shares in the last quarter. FMR LLC grew its stake in Sangamo Therapeutics by 16.5% in the third quarter. FMR LLC now owns 544,003 shares of the biopharmaceutical company’s stock valued at $471,000 after acquiring an additional 77,032 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Sangamo Therapeutics by 5.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,103,326 shares of the biopharmaceutical company’s stock worth $956,000 after acquiring an additional 57,125 shares in the last quarter. Institutional investors and hedge funds own 56.93% of the company’s stock.

Sangamo Therapeutics Trading Down 16.7 %

Shares of SGMO opened at $2.35 on Thursday. The company’s fifty day simple moving average is $1.91 and its 200 day simple moving average is $1.11. Sangamo Therapeutics, Inc. has a 1-year low of $0.30 and a 1-year high of $3.18. The company has a market cap of $490.32 million, a price-to-earnings ratio of -3.13 and a beta of 1.15.

Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.07. The company had revenue of $49.41 million for the quarter, compared to analyst estimates of $26.55 million. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. During the same period in the previous year, the business earned ($0.34) EPS. As a group, research analysts forecast that Sangamo Therapeutics, Inc. will post -0.46 earnings per share for the current year.

Wall Street Analyst Weigh In

SGMO has been the subject of several research analyst reports. Truist Financial upgraded Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $7.00 price objective for the company in a research report on Friday, December 13th. StockNews.com raised shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday. Barclays upped their target price on shares of Sangamo Therapeutics from $3.00 to $9.00 and gave the stock an “overweight” rating in a research note on Thursday, November 14th. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Sangamo Therapeutics in a research note on Tuesday, December 10th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, Sangamo Therapeutics has an average rating of “Moderate Buy” and an average price target of $7.00.

Sangamo Therapeutics Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.